HRP20201848T1 - Bispecifična egfr/c-met antitijela - Google Patents

Bispecifična egfr/c-met antitijela Download PDF

Info

Publication number
HRP20201848T1
HRP20201848T1 HRP20201848TT HRP20201848T HRP20201848T1 HR P20201848 T1 HRP20201848 T1 HR P20201848T1 HR P20201848T T HRP20201848T T HR P20201848TT HR P20201848 T HRP20201848 T HR P20201848T HR P20201848 T1 HRP20201848 T1 HR P20201848T1
Authority
HR
Croatia
Prior art keywords
cancer
antibody
egfr
met
amino acid
Prior art date
Application number
HRP20201848TT
Other languages
English (en)
Inventor
Mark Chiu
Sheri MOORES
Joost Neijssen
Paul Parren
Janine Schuurman
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50728148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20201848(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of HRP20201848T1 publication Critical patent/HRP20201848T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (11)

1. Izolirano bispecifično (c-Met) antitijelo specifično za receptor epidermalnog faktora rasta (EGFR)/receptor faktora rasta hepatocita, koje sadrži: a) prvi teški lanac (HC1) koji sadrži HC1 konstantnu domenu 3 (HC1 CH3) i HC1 varijabilnu regiju 1 (VH1); b) drugi teški lanac (HC2) koji sadrži HC2 konstantnu domenu 3 (HC2 CH3) i HC2 varijabilnu regiju 2 (VH2); c) prvi laki lanac (LC1) koji sadrži varijabilnu regiju 1 lakog lanca (VL1); i d) drugi laki lanac (LC2) koji sadrži varijabilnu regiju 2 lakog lanca (VL2), pri čemu se VH1 i VL1 spajaju radi stvaranja prvog mjesta za vezivanje antigena koji specifično veže EGFR, VH2 i VL2 se spajaju radi stvaranja drugog mjesta za vezivanje antigena koji specifično veže c-Met, HC1 sadrži najmanje jednu zamjenu u HC1 CH3 i HC2 sadrži najmanje jednu zamjenu u HC2 CH3, i zamjenu u HC1 CH3 i zamjenu u HC2 CH3 koja se pojavljuje na različitim položajima ostatka aminokiselina, kada je numeriranje ostataka u skladu sa EU indeksom, gdje i) VH1 sadrži regiju određivanja komplementarnosti teškog lanca (HCDR) 1 (HCDR1), HCDR2 i HCDR3 aminokiselinskih sekvenci SEQ ID NOs: 210, 211 i 212, tim redom; i ii) VL1 sadrži regiju određivanja komplementarnosti lakog lanca (LCDR) 1 (LCDR1), LCDR2 i LCDR3 aminokiselinskih sekvenci SEQ ID NOs: 213, 214 i 215, tim redom; i iii) VH2 sadrži HCDR1, HCDR2, i HCDR3 aminokiselinskih sekvenci SEQ ID NOs: 216, 217 i 218, tim redom; i iv) VL2 sadrži LCDR1, LCDR2 i LCDR3 aminokiselinskih sekvenci SEQ ID NOs: 219, 220 i 221, tim redom.
2. Bispecifično antitijelo prema zahtjevu 1, gdje: a) antitijelo je ljudsko antitijelo u kome VH1, VL1, VH2 i VH2 sadrže sekvencu aminokiselina SEQ ID NOs: 189, 190, 193 i 194, tim redom; i/ili b) antitijelo inhibira fosforilaciju kinaza 1 i 2 koje su povezane sa izvanstaničnim signalom (ERK1/2) u NCI-H292, NCI-H1975 ili SKMES-1 staničnoj liniji sa IC50 vrijednosti koja je najmanje 10-puta manja, najmanje 20-puta manja, najmanje 30-puta manja, najmanje 40-puta manja, najmanje 50-puta manja ili najmanje 60-puta manja u usporedbi sa IC50 vrijednosti inhibiranja fosforilacije ERK1/2 u NCI-H292, NCI-H1975 ili SKMES-1 staničnim linijama sa smjesom kontrolnog monovalentnog EGFR antitijela koji sadrži teški lanac 3 (HC3) i laki lanac 3 (LC3) i kontrolno monovalentno c-Met antitijelo koje sadrži teški lanac 4 (HC4) i laki lanac 4 (LC4), pri čemu HC3 i HC1, LC3 i LC1, HC4 i HC2, i LC4 i LC2 imaju redom identične sekvence aminokiselina, i fosforilacija ERK1/2 se mjeri u cijelim staničnim lizatima pomoću sendvič imunotesta upotrebom antifosfo ERK1/2 antitijela kao antitijela za hvatanje i antitijela koja se vežu za nefosforilni i fosforilni ERK1/2 koji je konjugiran sa elektrohemiluminscentnim spojem kao antitijelom za detekciju, opcionalno gdje: i) antitijelo inhibira fosforilaciju ERK1/2 sa IC50 vrijednosti 2x10-9 M ili manje, 1x10-9 M ili manje, ili 1x10-10 M ili manje; i/ili ii) ERK1 je fosforilan na položajima Thr202 i Tyr204, i ERK2 je fosforilan na ostacima Thr185 i Tyr197; i/ili i/ili; c) antitijelo koje inhibira fosforilaciju proteina kinaze B (AKT) na Ser473 u NCI-H1975 staničnoj liniji sa IC50 vrijednosti koja je najmanje 70-puta manja kada se usporedi sa IC50 vrijednosti inhibiranja fosforilacije AKT na Ser473 u NCI-H1975 staničnoj liniji s smjesom kontrolnog monovalentnog EGFR antitijela koje sadrži HC3 i LC3 i kontrolnog monovalentnog c-Met antitijela koje sadrži HC4 i LC4, gdje HC3 i HC1, LC3 i LC1, HC4 i HC2, i LC4 i LC2 imaju redom identične sekvence aminokiselina, i fosforilacija AKT na Ser473 se mjeri u cijelim staničnim lizatima sendvič imunotestom upotrebom antitijela koje se veže za nefosforilni i fosforilni AKT kao antitijelo za hvatanje i anti-fosfoAKT Ser473 antitijelom konjugiranim s elektrohemiluminiscentnim spojem kao antitijelo za detekciju, opcionalno gdje antitijelo inhibira fosforilaciju AKT na Ser473 s IC50 vrijednosti 1x10-9 M ili manje; i/ili d) antitijelo koje inhibira fosforilaciju AKT na Thr308 u NCI-H1975 staničnoj liniji s IC50 vrijednosti koja je najmanje 100-puta manja u usporedbi s IC50 vrijednosti inhibiranja fosforilacije AKT na Thr308 u NCIH1975 staničnoj liniji s smjesnom kontrolnog monovalentnog EGFR antitijela koje sadrži HC3 i LC3 kontrolno monovalentno c-Met antitijelo koje sadrži HC4 i LC4, gdje HC3 i HC1, LC3 i LC1, HC4 i HC2, i LC4 i LC2 imaju redom identične sekvence aminokiselina, i fosforilacija AKT na Thr308 se mjeri u cijelim staničnim lizatima sendvič imunotestom upotrebom antitijela koje se vezuje za nefosforilni i fosforilni AKT kao antitijelo za hvatanje i antifosfo AKT Thr308 antitijelom konjugiranim s elektrohemiluminiscentnim spojem kao antitijelo za detekciju, opcionalno gdje antitijelo inhibira fosforilaciju AKT na Thr308 s IC50 vrijednosti od 1x10-9 M ili manje; i/ili; e) bispecifično antitijelo veže EGFR koje ima sekvencu aminokiselina prikazanu u SEQ ID NO: 73 na EGFR ostacima K489, 1491, K467 i S492 i c-Met na ostacima PEFRDSYPIKYVHAF (SEQ ID NO: 238) i FAQSKPDSAEPMDRSA (SEQ ID NO: 239); i/ili f) antitijelo inhibira rast NCI-H292 ili NCI-H1975 stanica s IC50 vrijednosti koja je najmanje 300-puta manja, najmanje 400-puta manja, najmanje 500-puta manja, najmanje 600-puta manja, najmanje 700-puta manja ili najmanje 800-puta manja u usporedbi s IC50 vrijednosti inhibiranja rasta NCI-H292 ili NCI-H1975 stanica sa cetuksimabom kada se NCI-H292 ili NCI-H1975 stanice uzgajaju u uvjetima koji osiguravaju nisko vezivanje; i/ili g) antitijelo inhibira rast SKMES-1 tumorskih stanica koje eksprimiraju HGF u SCID Beige miševima s postotkom (%) T/C vrijednosti od najmanje 500-puta manje u danu 36 u usporedbi scetuksimabom, kada se bispecifično antitijelo i cetuksimab daju u dozi od 20 mg/kg ; i/ili; h) antitijelo neutralizira EGFR i c-Met signalne puteve.
3. Bispecifično antitijelo prema zahtjevu 1 ili zahtjevu 2, pri čemu HC1 i HC2 su od IgG1, IgG2, IgG3 ili IgG4 izotipa, na primjer gdje HC1 i HC2 su od IgG1 izotipa; opcionalno gdje HC1 CH3 sadrži najmanje jedan, dva, tri, četiri, pet, šest, sedam ili osam zamjena i HC2 CH3 sadrži najmanje jednu, dvije, tri, četiri, pet, šest, sedam ili osam zamjena na položajima ostatka 350, 366, 368, 370, 399, 405, 407 ili 409, pri čemu je numeriranje ostataka u skladu sa EU indeksom, što je a) gdje HC1 CH3 sadrži najmanje jednu, dvije, tri ili četiri zamjene i HC2 CH3 sadrži najmanje jednu, dvije, tri ili četiri zamjene na položajima ostataka 350, 370, 405 ili 409; b) gdje HC1 CH3 sadrži najmanje jednu zamjenu i HC2 CH3 sadrži najmanje jednu zamjenu na položajima ostataka 405 ili 409; c) gdje HC1 CH3 sadrži K409R ili F405L zamjenu i HC2 CH3 sadrži K409R ili F405L zamjenu; ili d) gdje HC1 CH3 sadrži F405L zamjenu i HC2 CH3 sadrži K409R zamjenu.
4. Bispecifično antitijelo prema bilo kojem od zahtjeva 1 do 3, (a) koje dalje sadrži 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 ili 15 konzervativnih zamjena aminokiselina u HC1, LC1, HC2 ili LC2, koji opcionalno sadrži zamjenu M252Y/S254T/T256E u HC1 i/ili HC2, pri čemu je numeriranje ostataka u skladu sa EU indeksom; i/ili (b) gdje antitijelo ima biantenarnu strukturu glikana sa sadržajem fukoze između 1 do 15%.
5. Farmaceutski sastav koji sadrži bispecifično antitijelo prema bilo kojem od zahtjeva 1 do 4 i farmaceutsko prihvatljivi nosač.
6. Bispecifično antitijelo prema bilo kojem od zahtjeva 1 do 4 za upotrebu u postupku liječenja raka, koji obuhvaća davanje terapeutski efikasne količine bispecifičnog EGFR/c-Met antitijela pacijentu kojem je potrebno u vremenskom periodu koji je dovoljan za liječenje raka, opciono gdje: a) rak je povezan sa mutacijom koja aktivira EGFR, umnožavanjem gena za EGFR, povećanim nivoima kruženja HGF, mutacijom koja aktivira c-Met, umnožavanjem gena za c-Met ili mutiranim KRAS, kao što je: (i) mutacija koja aktivira EGFR je G719A, G719X (pri čemu je X bilo koja aminokiselina), L861X (pri čemu je X bilo koja aminokiselina), L858R, E746K, L747S, E749Q, A750P, A755V, V765M, L858P ili T790M zamjena, brisanje E746-A750, brisanje R748-P753, unos Ala (A) između M766 i A767, unos Ser, Val i Ala (SVA) između S768 i V769, i unos Asn i Ser (NS) između P772 i H773, opcionalno gdje mutacija koja aktivira EGFR je L858R, del(E476, A750) i/ili T790M zamjena; ili (ii) mutirani KRAS ima G12V ili G12C zamjenu; ili (iii) subjekt je otporan ili je stekao otpornost na liječenje s erlotinibom, gefitinibom, afatinibom, CO-1686, AZD9192 ili cetuksimabom; ili (iv) rak je rak epitelnih stanica, rak grudi, rak jajnika, rak pluća, ne-sitnostanični rak pluća (NSCLC), adenokarcinom pluća, rak malih stanica pluća, kolorektalni rak, analni rak, rak prostate, rak bubrega, rak mjehura, rak glave i vrata, rak ždrijela, rak nosa, rak gušterače, rak kože, oralni rak, rak jezika, rak jednjaka, vaginalni rak, i rak vrata maternice, rak slezena, rak testisa, rak želuca, rak prsne žlijezde, rak debelog crijeva, rak štitne žlijezde, rak jetre, hepatocelularni rak (HCC) ili sporedni ili sporadični rak papilarnih bubrežnih stanica(PRCC); ili b) subjekt je homozigot za fenilalanin na položaju 158 od CD16 ili heterozigot za valin i fenilalanin na položaju 158 od CD16.
7. Bispecifično antitijelo za upotrebu prema zahtjevu 6 (a)(iv), koja obuhvaća davanje drugog terapeutskog sredstva, opcionalno gdje: a) drugo terapeutsko sredstvo je hemoterapeutsko sredstvo ili ciljana protiv raka terapija, kao što je: i) hemioterapeutsko sredstvo je cisplatin ili vinblastin; ili ii) hemioterapeutsko sredstvo ili ciljana protiv raka terapija je tirozin kinazni inhibitor EGFR, c-Met, HER2, HER3, HER4 ili VEGFR, opcionalno gdje je tirozin kinazni inhibitor erlotinib, gefitinib ili afatinib; ili b) drugo terapeutsko sredstvo se daje istovremeno, stupnjevito ili odvojeno.
8. Postupak in vitro inhibiranja rasta ili proliferacije stanica koje eksprimiraju EGFR i/ili c-Met, koji obuhvaća kontakt stanica sa bispecifičnim antitijelom prema bilo kojem od zahtjeva 1-4.
9. Bispecifično antitijelo prema bilo kojem od zahtjeva 1 do 4 za upotrebu u postupku inhibiranja rasta ili metastaza tumora ili stanica raka koje eksprimiraju EGFR i/ili c-Met kod subjekta koji obuhvaća davanje subjektu efikasne količine bispecifičnog antitijela za inhibiranje rasta ili metastaza tumora ili raka stanica koje eksprimiraju EGFR i/ili c-Met, opcionalno gdje je tumor koji eksprimira EGFR i/ili c-Met rak epitelnih stanica, rak grudi, rak jajnika, rak pluća, ne-sitnostanični rak pluća (NSCLC), adenokarcinom pluća, rak malih stanica pluća, kolorektalni rak, analni rak, rak prostate, rak bubrega, rak mjehura, rak glave i vrata, rak ždrijela, rak nosa, rak gušterače, rak kože, oralni rak, rak jezika, rak jednjaka, vaginalni rak, rak vrata maternice, rak slezena, rak testisa, rak želuca, rak prsne žlijezde, rak debelog crijeva, rak štitne žlijezde, rak jetre, hepatocelularni karcinom (HCC) ili sporedni ili nasljedni rak papilarnih stanica (PRCC), kao što gdje je tumor koji eksprimira EGFR i/ili c-Met povezan sa mutacijom koja aktivira EGFR, umnožavanjem gena za EGFR, povećanim nivoima kruženja HGF, mutacijom koja aktivira c-Met, umnožavanjem gena za c-Met ili mutiranog KRAS, opcionalno gdje: a) mutacija koja aktivira EGFR je G719A, G719X (pri čemu je X bilo koja aminokiselina), L861X (pri čemu je X bilo koja aminokiselina), L858R, E746K, L747S, E749Q, A750P, A755V, V765M, L858P ili T790M zamjena, brisanje E746-A750, brisanje R748-P753, unos Ala (A) između M766 i A767, i unos Ser, Val i Ala (SVA) između S768 i V769, i unos Asn i Ser (NS) između P772 i H773; ili b) mutirani KRAS ima G12V ili G12C zamjenu.
10. Bispecifično antitijelo prema bilo kojem od zahtjeva 1 do 4 za upotrebu u terapiji, kao što je za upotrebu u liječenju raka, opcionalno kada je rak rak epitelnih stanica, rak grudi, rak jajnika, rak pluća, ne-sitnostanični rak pluća (NSCLC), adenokarcinom pluća, rak malih stanica pluća, kolorektalni rak, analni rak, rak prostate, rak bubrega, rak mjehura, rak glave i vrata, rak ždrijela, rak nosa, rak gušterače, rak kože, oralni rak, rak jezika, rak jednjaka, vaginalni rak, rak vrata maternice, rak slezena, rak testisa, rak želuca, rak prsne žlijezde, rak debelog crijeva, rak štitne žlijezde, rak jetre, hepatocelularni karcinom (HCC) ili sporedni ili nasljedni karcinom papilarnih stanica bubrega (PRCC).
11. Bispecifično antitijelo za upotrebu prema zahtjevu 10, gdje je bispecifično antitijelo davano u kombinaciji s drugim terapeutskim agensom, istovremeno, stupnjevito ili odvojeno, opcionalno gdje drugi terapeutski agens je hemoterapeutski agens, kao što su: a) alkilirajuće sredstvo kao što su tiotepa i ciklosfosfamid; b) alkil sulfonat kao što su busulfan, improsulfan i piposulfan; c) aziridini kao što su benzodopa, karbohion, meturedopa, i uredopa; d) etilenimin i metilamelamin uključujući altretamin, trietilenmelamin, trietilenfosforamid, trietilentiofosfaoramid i trimetilolomelamin; e) azotni iperit kao što su hlorambucil, hlornafazin, holofosfamid, estramustin, ifosfamid, mehloretamin, mehloretamin oksid hidrohlorid, melfalan, novembihin, fenesterin, prednimustin, trofosfamid, uracil iperit; f) nitrozurea kao što su karmustin, hlorozotocin, fotemustin, lomustin, nimustin, ranimustin; g) antibiotik kao što je aklacinomisini, aktinomicin, autramicin, azaserin, bleomicini, kaktinomicin, kaliheamicin, karabicin, karminomicin, karzinofilin, hromomicini, daktinomicin, daunorubicin, detorubicin, 6-diazo-5-okso-L-norleucin, doksorubicin, epirubicin, ezorubicin, idarubicin, marcelomicin, mitomicini, mikofenolna kiselina, nogalamicin, olivomicini, peplomicin, potfiromicin, puromicin, hielamicin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimeks, zinostatin, zorubicin; h) anti-metabolit kao što je metotreksat i 5-FU; i) analog folne kiseline kao što su denopterin, metotreksat, pteropterin, trimetreksat; j) purinski analog kao što su fludarabin, 6-merkaptopurin, tiamiprin, tioguanin; k) analog pirimidina kao što su ancitabin, azacitidin, 6-azauridin, karmofur, citarabin, dideoksiuridin, doksifluridin, enocitabin, floksuridin; l) androgen kao što su kalusteron, dromostanolon propionat, epitiostanol, mepitiostan, testolakton; m) anti-andrenalni kao što su aminoglutetimid, mitotan, trilostan; n) dopuna folne kiseline kao što je frolinska kiselina; o) aceglaton; aldofosfamid glikozid; aminolevulinska kiselina; amsakrin; bestrabucil; bisantren; edatraksat; defofamin; demekolcin; diazihion; elfornitin; eliptinium acetat; etoglucid; galijum nitrat; hidroksiurea; lentinan; jonidamin; mitoguazon; mitoksantron; mopidamol; nitracrin; pentostatin; fenamet; pirarubicin; podofilin kiselina; 2-etilhidrazid; prokarbazin; PSK®; razoksan; sizofiran; spirogermanijum; tenuazonska kiselina; triazihion; 2,2’,2"-trihlorotrietilamin; uretan; vindezin; dakarbazin; manomustin; mitobronitol; mitolaktol; pipobroman; gakitozin; arabinozid; ciklofosfamid; ili tiotepa; p) član taksoida ili obitelji taksana, kao što su paklitaksel i njihovi analozi; hlorambucil; gemcitabin; 6-tioguanin; merkaptopurin; metotreksat; q) analog platine kao što su cisplatin i karboplatin; r) vinblastin; platina; etopozid (VP-16); ifosfamid; mitomicin C; mitoksantron; vinkristin; vinorelbin; navelbin; novantron; tenipozid; daunomicin; aminopterin; kseloda; ibandronat; CPT-11; inhibitor topoizomeraze RFS 2000; difluorometilornitin (DMFO); retinoinska kiselina; esperamicini; ili kapecitabin; s) inhibitor receptorskih tirozin kinaza i/ili angiogeneze, uključujući sorafenib, sunitinib pazopanib, toceranib, vandetanib, cediranib, regorafenib, aksitinib (AG013736), lestaurtinib, erlotinib, gefitinib, BIBW 2992, lapatinib, neratinib t) anti-hormonalno sredstvo koje djeluje tako što regulira ili inhibira djelovanje hormona na tumore kao što su anti-estrogeni uključujući na primjer tamoksifen, raloksifen, aromataza inhibirajuće 4(5)-imidazole, 4-hidroksitamoksifen, trioksifen, keoksifen, LI 117018, onapriston, i toremifen; ili u) anti-androgen kao što su flutamid, nilutamid, bikalutamid, leuprolid, i goserelin; i farmaceutski prihvatljive soli, kiseline ili derivate od bilo koga gore navedenog.
HRP20201848TT 2012-11-21 2020-11-20 Bispecifična egfr/c-met antitijela HRP20201848T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261728912P 2012-11-21 2012-11-21
US201361782550P 2013-03-14 2013-03-14
US201361809541P 2013-04-08 2013-04-08
US201361864717P 2013-08-12 2013-08-12
US201361892797P 2013-10-18 2013-10-18
EP18199421.1A EP3447069B1 (en) 2012-11-21 2013-11-21 Bispecific egfr/c-met antibodies

Publications (1)

Publication Number Publication Date
HRP20201848T1 true HRP20201848T1 (hr) 2021-01-08

Family

ID=50728148

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20182128TT HRP20182128T1 (hr) 2012-11-21 2013-11-21 Bispecifična egfr/c-met protutijela
HRP20201848TT HRP20201848T1 (hr) 2012-11-21 2020-11-20 Bispecifična egfr/c-met antitijela

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20182128TT HRP20182128T1 (hr) 2012-11-21 2013-11-21 Bispecifična egfr/c-met protutijela

Country Status (36)

Country Link
US (3) US9593164B2 (hr)
EP (4) EP3447069B1 (hr)
JP (5) JP6423357B2 (hr)
KR (4) KR20250054125A (hr)
CN (2) CN113201073A (hr)
AU (4) AU2013347962B2 (hr)
BR (1) BR112015011717B1 (hr)
CA (2) CA2893505C (hr)
CL (1) CL2015001356A1 (hr)
CY (2) CY1121270T1 (hr)
DK (2) DK2922872T3 (hr)
EA (1) EA031184B1 (hr)
ES (3) ES2971536T3 (hr)
FI (1) FIC20220016I1 (hr)
FR (1) FR22C1018I2 (hr)
HR (2) HRP20182128T1 (hr)
HU (3) HUE041499T2 (hr)
IL (1) IL238796B (hr)
LT (3) LT3447069T (hr)
LU (1) LUC00257I2 (hr)
MX (1) MX361088B (hr)
MY (1) MY172867A (hr)
NI (1) NI201500069A (hr)
NL (1) NL301173I2 (hr)
NO (1) NO2022012I1 (hr)
NZ (1) NZ708352A (hr)
PE (1) PE20151181A1 (hr)
PH (1) PH12015501118A1 (hr)
PL (1) PL2922872T3 (hr)
PT (2) PT3447069T (hr)
RS (2) RS61057B1 (hr)
SG (1) SG11201503938VA (hr)
SI (2) SI2922872T1 (hr)
SM (2) SMT201800624T1 (hr)
UA (1) UA117121C2 (hr)
WO (1) WO2014081954A1 (hr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681974C (en) 2007-03-29 2019-12-31 Genmab A/S Bispecific antibodies and methods for production thereof
ES2609043T3 (es) * 2009-11-30 2017-04-18 Janssen Biotech, Inc. Anticuerpos mutantes Fc con funciones de efecto abladas
CN103003307B (zh) * 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
PL2560993T3 (pl) * 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
NZ604003A (en) 2010-05-27 2015-04-24 Genmab As Monoclonal antibodies against her2
SG10201805291TA (en) 2011-10-27 2018-08-30 Genmab As Production of heterodimeric proteins
SI2922872T1 (sl) * 2012-11-21 2019-01-31 Janssen Biotech, Inc., Bispecifična protitelesa EGFR/C-MET
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
US10196446B2 (en) 2013-10-14 2019-02-05 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
CA2938818C (en) * 2014-02-04 2023-03-07 Astellas Pharma Inc. Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
WO2015130172A1 (en) 2014-02-28 2015-09-03 Merus B.V. Antibodies that bind egfr and erbb3
KR102309881B1 (ko) 2014-11-21 2021-10-06 삼성전자주식회사 c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
US10507210B2 (en) * 2014-12-03 2019-12-17 Auckland Uniservices Limited Kinase inhibitor prodrug for the treatment of cancer
WO2016100233A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
US11253546B2 (en) * 2014-12-15 2022-02-22 The Regents Of The University Of California Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
US10865253B2 (en) 2014-12-19 2020-12-15 Genmab A/S Rodent bispecific heterodimeric proteins
WO2016106158A1 (en) * 2014-12-22 2016-06-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016182513A1 (en) * 2015-05-13 2016-11-17 Singapore Health Services Pte Ltd Profiling of hepatocellular carcinoma and applications thereof
SG11201803359VA (en) 2015-10-23 2018-05-30 Merus Nv Binding molecules that inhibit cancer growth
CN108350078A (zh) * 2015-11-03 2018-07-31 默克专利股份公司 用于提高肿瘤选择性和抑制的双特异性抗体及其用途
CA3004138A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and tim-3 and their uses
AU2017214692B2 (en) * 2016-02-06 2021-11-04 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
KR20220130249A (ko) 2016-05-26 2022-09-26 리커리엄 아이피 홀딩스, 엘엘씨 Egfr 억제제 화합물
KR101985299B1 (ko) * 2016-06-03 2019-09-03 삼성전자주식회사 항-c-Met/항-Nrp1 이중 특이 항체
MX2018016185A (es) * 2016-06-21 2019-03-28 Janssen Biotech Inc Moléculas de unión al dominio de fibronectina tipo iii diseñadas de cisteína.
KR20190057308A (ko) 2016-09-02 2019-05-28 더 리전츠 오브 더 유니버시티 오브 캘리포니아 인터류킨-6 수용체 알파-결합 단일 사슬 가변 단편을 포함하는 방법 및 조성물
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
EP3541423A4 (en) * 2016-11-18 2020-10-07 The Regents of The University of California MODIFIED ANTIBODIES AND THEIR USES
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
AU2017378226A1 (en) 2016-12-14 2019-06-20 Janssen Biotech, Inc. CD8A-binding fibronectin type III domains
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
TWI723247B (zh) * 2017-02-06 2021-04-01 中央研究院 重組蛋白及其用途
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
BR112019024230A2 (pt) 2017-05-17 2020-06-09 Merus N.V. combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama
MX2019014316A (es) * 2017-05-30 2020-01-27 Chong Kun Dang Pharmaceutical Corp Un nuevo anticuerpo anti-c-met y uso del mismo.
WO2018221969A1 (en) * 2017-05-30 2018-12-06 Chong Kun Dang Pharmaceutical Corp. A novel anti-c-met antibody and use thereof
SG11202001050PA (en) * 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
CA3074317C (en) * 2017-08-25 2024-06-18 Janssen Biotech, Inc. Fc.gamma.rii binding fibronectin type iii domains, their conjugates and multispecific molecules comprising them
CN109912716B (zh) * 2017-12-13 2022-08-23 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
US20190184028A1 (en) * 2017-12-14 2019-06-20 Janssen Biotech, Inc. Targeting with firbronectin type iii like domain molecules
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
JOP20200303A1 (ar) 2018-05-24 2020-11-23 Janssen Biotech Inc عوامل ربط psma واستخداماتها
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
CN112955137B (zh) * 2018-09-10 2025-05-13 米拉蒂治疗股份有限公司 组合疗法
EP3849535A4 (en) * 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
CR20210193A (es) 2018-10-22 2021-06-15 Janssen Pharmaceutica Nv Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas
SG11202102357RA (en) 2018-12-05 2021-04-29 Mirati Therapeutics Inc Combination therapies
TWI874341B (zh) * 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
SG11202108311RA (en) * 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
CA3136888A1 (en) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
MY208668A (en) * 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
SG11202112412QA (en) * 2019-05-14 2021-12-30 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
KR20220063185A (ko) 2019-09-16 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
CN116194141A (zh) * 2020-08-25 2023-05-30 詹森生物科技公司 具有egfr突变的非小细胞肺癌的治疗
AR123340A1 (es) * 2020-08-26 2022-11-23 Janssen Biotech Inc FORMULACIONES ESTABLES QUE COMPRENDEN UN ANTICUERPO BIESPECÍFICO PARA EGFR / c-MET
EP4210702A1 (en) * 2020-09-14 2023-07-19 JANSSEN Pharmaceutica NV Fgfr inhibitor combination therapies
KR20230137393A (ko) 2021-01-28 2023-10-04 얀센 바이오테크 인코포레이티드 Psma 결합 단백질 및 이의 용도
AU2022233518A1 (en) 2021-03-09 2023-10-26 Janssen Biotech, Inc. Treatment of cancers lacking egfr-activating mutations
BR112023021318A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Conjugados de domínio fn3-sirna e usos dos mesmos
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
TW202308689A (zh) * 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
TW202309094A (zh) 2021-05-18 2023-03-01 美商健生生物科技公司 用於識別癌症患者以進行組合治療之方法
EP4372001A4 (en) * 2021-07-14 2025-02-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO HGFR AND EGFR, AND PHARMACEUTICAL USE THEREOF
EP4405398A4 (en) 2021-09-21 2025-10-29 Qilu Puget Sound Biotherapeutics Corp FC HETERODIMERS ALLOWING THE MANUFACTURE OF FUSION PROTEINS AND BI-SPECIFIC ANTIBODIES
CA3232216A1 (en) * 2021-10-18 2023-04-27 Tavotek Biotherapeutics (Hong Kong) Limited Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereof
US20230183360A1 (en) * 2021-12-09 2023-06-15 Janssen Biotech, Inc. Use of Amivantamab to Treat Colorectal Cancer
WO2023142996A1 (zh) 2022-01-28 2023-08-03 上海岸阔医药科技有限公司 预防或治疗与抗肿瘤剂相关的疾病或病症的方法
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
KR20240150493A (ko) 2022-02-21 2024-10-15 온퀄리티 파마슈티컬스 차이나 리미티드 화합물 및 그 용도
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法
KR20250028357A (ko) * 2022-06-29 2025-02-28 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 항-egfr/met 항체 및 이의 용도
WO2024003837A1 (en) * 2022-06-30 2024-01-04 Janssen Biotech, Inc. Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer
TW202430566A (zh) * 2022-11-24 2024-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種包含特異性結合ｈｇｆｒ和ｅｇｆｒ的雙特異性抗體的醫藥組成物
CN120882752A (zh) 2023-03-13 2025-10-31 詹森生物科技公司 双特异性抗EGFR/c-Met抗体和抗PD-1抗体的组合疗法
WO2024193449A1 (en) * 2023-03-17 2024-09-26 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-her3 and anti-met antibodies and uses thereof
EP4454706A1 (en) * 2023-04-24 2024-10-30 Universität Stuttgart Novel egfr binding proteins
TW202500584A (zh) 2023-05-19 2025-01-01 法商施維雅藥廠 抗met抗體、抗體-藥物結合物、組合物及其用途
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
UY40783A (es) 2023-06-12 2024-12-31 Amgen Inc Proteínas de unión a agonistas del receptor beta de linfotoxina
TW202502822A (zh) * 2023-07-07 2025-01-16 大陸商四川科倫博泰生物醫藥股份有限公司 Ｅｇｆｒ／ｃ－ｍｅｔ雙特異性結合蛋白及其用途
WO2025017409A1 (en) 2023-07-14 2025-01-23 Janssen Biotech, Inc. Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies
WO2025025434A1 (zh) * 2023-08-02 2025-02-06 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
TW202519556A (zh) * 2023-09-28 2025-05-16 大陸商上海翰森生物醫藥科技有限公司 雙特異性抗體在製備治療癌症的藥物中的用途
WO2025079020A1 (en) 2023-10-12 2025-04-17 Janssen Biotech, Inc. First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
CN120000805A (zh) * 2023-11-15 2025-05-16 四川科伦博泰生物医药股份有限公司 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途
WO2025131053A1 (en) * 2023-12-22 2025-06-26 Fortvita Biologics Inc. Bispecific antibody-drug conjugates targeting b7h3 and egfr and the use thereof
WO2025153988A1 (en) 2024-01-16 2025-07-24 Janssen Biotech, Inc. Use of amivantamab to treat colorectal cancer
WO2025158277A1 (en) 2024-01-22 2025-07-31 Janssen Biotech, Inc. Use of amivantamab to treat head and neck cancer
WO2025191459A1 (en) 2024-03-11 2025-09-18 Janssen Biotech, Inc. Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
WO2025247330A1 (zh) * 2024-05-31 2025-12-04 江苏先声生物制药有限公司 抗EGFR×cMet双特异性抗体的药物偶联物及其用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1991003489A1 (en) 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
JP3127158B2 (ja) 1989-10-05 2001-01-22 オプテイン，インコーポレイティド 新規の遺伝子及びポリペチドの無細胞合成並びに単離
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE247168T1 (de) 1991-03-06 2003-08-15 Merck Patent Gmbh Humanisierte monoklonale antikörper
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
JP4414142B2 (ja) 2001-05-11 2010-02-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 特異的結合タンパク質およびその使用
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
AU2002345673B2 (en) * 2001-06-13 2007-04-26 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
EP2385118A1 (en) 2002-09-06 2011-11-09 Isogenica Limited In vitro peptide expression library
MXPA05008521A (es) 2003-02-13 2005-10-20 Pharmacia Corp Anticuerpos a c-met para el tratamiento de canceres.
KR101254371B1 (ko) * 2003-07-18 2013-05-02 암젠 프레몬트 인코포레이티드 간세포 성장인자에 결합하는 분리된 항체
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
WO2005118876A2 (en) 2004-06-04 2005-12-15 Genentech, Inc. Egfr mutations
RU2398777C2 (ru) 2004-08-05 2010-09-10 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
EP2851091B1 (en) 2007-04-13 2017-12-27 Dana-Farber Cancer Institute, Inc. Methods for treating cancer resistant to ERBB therapeutics
US20090042906A1 (en) 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
WO2009030239A1 (en) * 2007-09-06 2009-03-12 Genmab A/S Novel methods and antibodies for treating cancer
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
JP2011507521A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ヒト非抗体ペプチド又はタンパク質ファージライブラリ
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
CN102014913A (zh) 2008-03-06 2011-04-13 健泰科生物技术公司 C-met和egfr拮抗剂的联合疗法
CL2009000843A1 (es) 2008-04-11 2009-07-24 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
AU2009281721A1 (en) * 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
WO2010039248A1 (en) 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
PT2356269T (pt) 2008-10-31 2016-09-13 Janssen Biotech Inc Composições, métodos e usos de scaffolds baseados em domínios de fibronectina tipo iii
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
EP2417160A1 (en) * 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-1/anti-c-met antibodies
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
RU2012112550A (ru) 2009-09-01 2013-10-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
ES2609043T3 (es) 2009-11-30 2017-04-18 Janssen Biotech, Inc. Anticuerpos mutantes Fc con funciones de efecto abladas
CN103003307B (zh) * 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
PL2560993T3 (pl) * 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
ES2730693T3 (es) 2010-04-30 2019-11-12 Janssen Biotech Inc Composiciones del dominio de fibronectina estabilizados, métodos y usos
AU2010355523B2 (en) * 2010-06-15 2014-09-11 Alberto Bardelli MLK4 gene, a new diagnostic and prognostic marker in cancers
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
CN114634572A (zh) * 2011-10-10 2022-06-17 希望之城公司 中间位和中间位结合抗体及其用途
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
SI2922872T1 (sl) * 2012-11-21 2019-01-31 Janssen Biotech, Inc., Bispecifična protitelesa EGFR/C-MET
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Also Published As

Publication number Publication date
LTC2922872I2 (hr) 2024-09-10
PL2922872T3 (pl) 2019-03-29
US9695242B2 (en) 2017-07-04
EP3808767C0 (en) 2023-12-06
MX361088B (es) 2018-11-26
SMT201800624T1 (it) 2019-01-11
ES2971536T3 (es) 2024-06-05
JP2022062155A (ja) 2022-04-19
KR20240005211A (ko) 2024-01-11
US9580508B2 (en) 2017-02-28
EP2922872A4 (en) 2016-07-06
MY172867A (en) 2019-12-13
KR20150087365A (ko) 2015-07-29
AU2021202394B2 (en) 2024-03-07
BR112015011717A2 (pt) 2017-08-15
KR102373193B1 (ko) 2022-03-10
JP7756699B2 (ja) 2025-10-20
MX2015006387A (es) 2015-12-03
CN104955838A (zh) 2015-09-30
SI2922872T1 (sl) 2019-01-31
JP2024026236A (ja) 2024-02-28
AU2013347962A1 (en) 2015-05-28
EP3447069B1 (en) 2020-09-23
CL2015001356A1 (es) 2015-11-06
AU2021202394A1 (en) 2021-05-20
SG11201503938VA (en) 2015-06-29
PT2922872T (pt) 2019-01-18
HRP20182128T1 (hr) 2019-02-08
EP2922872A1 (en) 2015-09-30
PT3447069T (pt) 2020-11-13
NO2022012I1 (no) 2022-05-06
EP4420727A2 (en) 2024-08-28
FIC20220016I1 (fi) 2022-05-31
FR22C1018I1 (fr) 2022-06-17
CN113201073A (zh) 2021-08-03
DK2922872T3 (da) 2019-01-02
EP4420727A3 (en) 2024-10-23
PE20151181A1 (es) 2015-08-19
US9593164B2 (en) 2017-03-14
AU2019200441A1 (en) 2019-02-07
SMT202000619T1 (it) 2021-01-05
KR20250054125A (ko) 2025-04-22
BR112015011717B1 (pt) 2023-12-12
CN104955838B (zh) 2021-02-02
FR22C1018I2 (fr) 2023-05-05
RS58192B1 (sr) 2019-03-29
IL238796B (en) 2019-06-30
LUC00257I2 (hr) 2025-04-25
JP2019048817A (ja) 2019-03-28
EP2922872B1 (en) 2018-10-10
AU2024203417A1 (en) 2024-06-13
US20140141000A1 (en) 2014-05-22
WO2014081954A1 (en) 2014-05-30
LTPA2022507I1 (hr) 2022-06-27
RS61057B1 (sr) 2020-12-31
JP6773746B2 (ja) 2020-10-21
JP6423357B2 (ja) 2018-11-14
LT2922872T (lt) 2018-12-27
CA2893505A1 (en) 2014-05-30
UA117121C2 (uk) 2018-06-25
ES2831374T3 (es) 2021-06-08
HUE041499T2 (hu) 2019-05-28
NL301173I1 (nl) 2022-05-04
NZ708352A (en) 2019-10-25
SI3447069T1 (sl) 2021-02-26
EA201590985A1 (ru) 2015-11-30
IL238796A0 (en) 2015-06-30
US20140255408A1 (en) 2014-09-11
CY1123550T1 (el) 2022-03-24
PH12015501118B1 (en) 2016-02-01
EP3808767A1 (en) 2021-04-21
HUS2200016I1 (hu) 2022-05-28
ES2700231T3 (es) 2019-02-14
EP3447069A1 (en) 2019-02-27
PH12015501118A1 (en) 2016-02-01
LT3447069T (lt) 2020-12-10
EA031184B1 (ru) 2018-11-30
JP7019771B2 (ja) 2022-02-15
KR20220032654A (ko) 2022-03-15
HUE052548T2 (hu) 2021-05-28
CA2893505C (en) 2023-02-21
AU2013347962B2 (en) 2018-10-25
NI201500069A (es) 2015-10-19
CA3182876A1 (en) 2014-05-30
EP3808767B1 (en) 2023-12-06
AU2019200441B2 (en) 2021-01-28
NL301173I2 (nl) 2022-06-15
CY1121270T1 (el) 2020-05-29
DK3447069T3 (da) 2020-11-16
US20170101475A1 (en) 2017-04-13
JP2021006561A (ja) 2021-01-21
KR102795571B1 (ko) 2025-04-11
JP2016505537A (ja) 2016-02-25
JP7397105B2 (ja) 2023-12-12

Similar Documents

Publication Publication Date Title
HRP20201848T1 (hr) Bispecifična egfr/c-met antitijela
CN111936164B (zh) 癌的治疗和/或预防用药物组合物
CN104271601B (zh) 使用pd-1轴结合拮抗剂和vegf拮抗剂治疗癌症的方法
CA2860941C (en) Combination therapy for the treatment of ovarian cancer
CA3175137A1 (en) Medicament for treatment and/or prevention of cancer
CA2793545A1 (en) Treatment methods
JPWO2021182573A5 (hr)
EP4582100A1 (en) Medicament for treatment and/or prevention of cancer
US20250228937A1 (en) Medicament for treatment and/or prevention of cancer
CA3175277A1 (en) Medicament for treatment and/or prevention of cancer
US20230165957A1 (en) Medicament for treatment and/or prevention of cancer
US20250281607A1 (en) Medicament for treatment and/or prevention of cancer
US20230140155A1 (en) Medicament for treatment and/or prevention of cancer
EP4578457A1 (en) Pharmaceutical for treating and/or preventing cancer
EP4578458A1 (en) Medicament for treatment and/or prevention of cancer
US20240325529A1 (en) Medicament for treatment and/or prevention of cancer
EP4582101A1 (en) Medicament for treatment and/or prevention of cancer
EP4640235A1 (en) Medicament for treatment and/or prevention of cancer
EA050561B1 (ru) Лечение немелкоклеточного рака легкого с мутациями egfr
AU2017202820A1 (en) Combination therapy with c-met and HER antagonists
HK1200857B (zh) 使用pd-1轴结合拮抗剂和vegf拮抗剂治疗癌症的方法